Erratum: Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial

被引：0

作者：

Wolfgang Gaebel

Andreas Schreiner

Paul Bergmans

Rosario de Arce

Frédéric Rouillon

Joachim Cordes

Lars Eriksson

Enrico Smeraldi

机构：

来源：

Neuropsychopharmacology | 2011年 / 36卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Correction to: Neuropsychopharmacology (2010) 35, 2367–2377; doi:10.1038/npp.2010.111; published online 4 August 2010 In this article, the authors would like to apologize for an error inadvertently introduced into the paper. During pre-marketing clinical studies, reactions that presented with signs and symptoms consistent with olanzapine overdose were reported in patients following an injection of olanzapine pamoate.

引用

页码：548 / 548

共 50 条

[31] A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea
Lee, Nam Young
Kim, Se Hyun
Cho, Seong Jin
Chung, Young-Cho
Jung, In Kwa
Kim, Chang Yoon
Kim, Duk Ho
Lee, Dong Geun
Lee, Yo Han
Lim, Weon Jeong
Na, Young Suk
Shin, Sang Eun
Woo, Jong-Min
Yoon, Jin Sang
Yoon, Bo-Hyun
Ahn, Yong Min
Kim, Yong Sik
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 279 - 287
[32] The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable
Gharabawi, Georges
Bossie, Cynthia
Turkoz, Ibrahim
Kujawa, Mary
Mahmoud, Ramy
Simpson, George
JOURNAL OF NERVOUS AND MENTAL DISEASE, 2007, 195 (12) : 976 - 982
[33] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
Rosa, Fernanda
Schreiner, Andreas
Thomas, Pierre
Sherif, Tarek
CLINICAL DRUG INVESTIGATION, 2012, 32 (04) : 267 - 279
[34] Switching Patients with Stable Schizophrenia or Schizoaffective Disorder from Olanzapine to Risperidone Long-Acting Injectable
Fernanda Rosa
Andreas Schreiner
Pierre Thomas
Tarek Sherif
Clinical Drug Investigation, 2012, 32 : 267 - 279
[35] Long-Acting Injectable vs Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Use Disorder: A Randomized Trial
Green, Alan I.
Brunette, Mary F.
Dawson, Ree
Buckley, Peter
Wallace, Amy E.
Hafez, Hisham
Herz, Marvin
Narasimhan, Meera
Noordsy, Douglas L.
O'Keefe, Christopher
Sommi, Roger W.
Steinbook, Richard M.
Weeks, Marjorie
JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (10) : 1359 - 1365
[36] Long-term remission in schizophrenia and related psychoses with long-acting risperidone: Results obtained in an open-label study with an observation period of 18 months
Llorca, P. -M.
Sacchetti, E.
Lloyd, K.
Kissling, W.
Medori, R.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2008, 46 (01) : 14 - 22
[37] Randomized comparison trial of oral atypicals vs long-acting injectable risperidone in patients with bipolar disorder
Binder, C.
Yatham, L. N.
Fallu, A.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S181 - S181
[38] Open-label over effectiveness of long-acting risperidone as maintenance therapy of bipolar and schizoaffective disorders
Castro-Loli, P.
Benabarre, A.
Martinez-Aran, A.
Sanchez-Moreno, J.
Salamero, M.
Murru, A.
Vieta, E.
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S409 - S409
[39] Response, remission and relapse during the long-term treatment of schizophrenia patients with long-acting injectable risperidone versus olanzapine
Potapov, A.
Eduard, T.
Sergey, M.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 158 - 158
[40] Young patients (18-30 years) with schizophrenia and schizoaffective disorder: Results of direct switching to long-acting injectable risperidone (Stormi trial)
Saleem, PT
Firmino, H
Parellada, E
SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 176 - 176

← 1 2 3 4 5 →